Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21034181 | 0.85 | ADRB2 (0.49) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL18980470 | 0.84 | DRD2 (0.52) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL6186822 | 0.84 | ADRB2 (0.62) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL17729186 | 0.83 | CHRM4 (0.53) | ALDH1A1FFAR4 | |
| SCHEMBL19000116 | 0.83 | ADRB2 (0.57) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL1729014 | 0.82 | DRD2 (0.52) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL29722401 | 0.81 | ADRB2 (0.58) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL18980471 | 0.81 | ADRB2 (0.58) | ADRB2NCF1KCNH2DRD2DRD3 | |
| SCHEMBL17729123 | 0.81 | FAAH (0.58) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29722226 | 0.80 | ADRB2 (0.57) | ADRB2NCF1KCNH2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| CN-111386114-A | Novel benzimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenase | 百济神州有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2019101188-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES | BEIGENE, LTD. (GB) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO2, IDO1, TPH2 | ADRB2 500/4885NCF1 1641/4885KCNH2 3467/4885 |
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | IDO1, IDO2, TPH2 | ADRB2 779/4885NCF1 1665/4885KCNH2 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.